Your AI-Trained Oncology Knowledge Connection!
Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.
Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.
Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Eileen O'Reilly, MD, discusses the utility of PARP inhibitors in pancreatic cancer.
Carlos E. Vargas, MD, examines the use of stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer.
Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).
Katherine Crew, MD, MS, discusses treatment for patients with favorable-risk early-stage HER2-positive breast cancer.
Girish Putcha, MD, PhD, discusses the results of the AI EMERGE trial (NCT03688906) in colorectal cancer.
R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.
Ryan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.
Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.
Farrukh Awan, MD, discusses the need for time-limited treatments in patients with chronic lymphocytic leukemia.
Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.
Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.
Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.
Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.
Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.
Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.
William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.
Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.
Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses the nuances of immunotherapy related adverse events in melanoma.
Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.
Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.
Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.
Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.
Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.
Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.
Aditya Bardia, MD, MPH, discusses the clinical utility of liquid biopsies in breast cancer.
Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.
Nancy Lin, MD, discusses central nervous system–specific outcomes with neratinib (Nerlyx) in HER2-positive breast cancer.
